Article info
PDFClinical trial
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation
- Correspondence to Professor Ana Oaknin, Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; aoaknin{at}vhio.net
Citation
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation
Publication history
- Accepted March 25, 2022
- First published April 20, 2022.
Article Versions
- You are currently viewing a Previous version of this article (20 April 2022).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.